Senhwa Biosciences
生華生物科技股份有限公司
Senhwa Biosciences is a Taiwan TPEx-listed biotechnology company; its most advanced asset is CX-5461 (First patient enrolled, Refractory microsatellite-stable colorectal cancer), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| CX-5461 | — | First patient enrolled | Refractory microsatellite-stable colorectal cancer | United States | 2026-09-07 | Company disclosure |
| CX-5461 + PD-1 inhibitor | — | Phase 1b/2a trial authorized | Advanced solid tumors | Taiwan, United States | 2026-08-06 | Company disclosure |
| CX-4945 | — | Phase 1/2 study; NCI funding not renewed | Recurrent SHH-subtype medulloblastoma | North America | 2026-03-27 | Company disclosure |
Key events
- CX-5461 Phase 1b enrollment completion announced (company disclosure)
- First patient enrolled in the NCI-sponsored CX-5461 plus cemiplimab colorectal cancer study (company disclosure)
- PBTC-led medulloblastoma Phase 1/2 study terminated after NCI sponsorship expired (company disclosure)